Hikma Pharmaceuticals PLC
Ouvert
SecteurSoins de santé
1,474 -0.81
Résumé
Variation du prix de l'action
24h
Min
1469
Max
1491
Revenu | 165M |
|---|---|
Ventes | 41M 1.7B |
P/E Moyenne du Secteur | 10.771 49.052 |
BPA | 1.07 |
Rendement du dividende | 5.74 |
Marge bénéficiaire | 9.698 |
Employés | 9,400 |
EBITDA | 152M 411M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +23.99% upside |
Rendement du dividende Moyenne du Secteur | 5.74% 2.36% |
|---|---|
Prochains Résultats | 6 août 2026 |
Date du Prochain Détachement de Dividende | 13 août 2026 |
Capitalisation Boursière | -526M 3.1B |
|---|---|
Ouverture précédente | 1474.81 |
Clôture précédente | 1474 |
Sentiment de l'Actualité
By Acuity
43%
57%
118 / 342 Classement par Healthcare
Hikma Pharmaceuticals PLC Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
